{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:19:38Z","timestamp":1792783178680,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National Natural Science Foundation of China's Post Grant Fund","award":["No. 2018YFC170610512"],"award-info":[{"award-number":["No. 2018YFC170610512"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the National Natural Science Foundation of China's Post Grant Fund","award":["No. 2018YFC170610512"],"award-info":[{"award-number":["No. 2018YFC170610512"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"DOI":"10.1007\/s00384-023-04376-y","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T01:57:57Z","timestamp":1680487077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of total neoadjuvant therapy in locally advanced rectal cancer: a meta-analysis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-0627","authenticated-orcid":false,"given":"Kai","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianbao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,1]]},"reference":[{"key":"4376_CR1","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.\u00a0CA Cancer J Clin\u00a071:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"4376_CR2","doi-asserted-by":"publisher","unstructured":"Miller KD et al (2022) Cancer treatment and survivorship statistics.\u00a0CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21731","DOI":"10.3322\/caac.21731"},{"key":"4376_CR3","doi-asserted-by":"publisher","first-page":"874","DOI":"10.6004\/jnccn.2018.0061","volume":"16","author":"AB Benson","year":"2018","unstructured":"Benson AB et al (2018) Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16:874\u2013901. https:\/\/doi.org\/10.6004\/jnccn.2018.0061","journal-title":"J Natl Compr Canc Netw"},{"key":"4376_CR4","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S1470-2045(17)30086-4","volume":"18","author":"J Erlandsson","year":"2017","unstructured":"Erlandsson J et al (2017) Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 18:336\u2013346. https:\/\/doi.org\/10.1016\/S1470-2045(17)30086-4","journal-title":"Lancet Oncol"},{"key":"4376_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ags3.12349","volume":"4","author":"HS Kim","year":"2020","unstructured":"Kim HS, Kim NK (2020) Challenges and shifting treatment strategies in the surgical treatment of locally advanced rectal cancer. Ann Gastroenterol Surg 4:379\u2013385. https:\/\/doi.org\/10.1002\/ags3.12349","journal-title":"Ann Gastroenterol Surg"},{"key":"4376_CR6","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/annonc\/mdu560","volume":"26","author":"AJ Breugom","year":"2015","unstructured":"Breugom AJ et al (2015) Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 26:696\u2013701. https:\/\/doi.org\/10.1093\/annonc\/mdu560","journal-title":"Ann Oncol"},{"key":"4376_CR7","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1200\/JCO.21.01667","volume":"40","author":"J Jin","year":"2022","unstructured":"Jin J et al (2022) Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J Clin Oncol 40:1681\u20131692. https:\/\/doi.org\/10.1200\/JCO.21.01667","journal-title":"J Clin Oncol"},{"key":"4376_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","volume":"12","author":"W van Gijn","year":"2011","unstructured":"van Gijn W et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575\u2013582. https:\/\/doi.org\/10.1016\/S1470-2045(11)70097-3","journal-title":"Lancet Oncol"},{"key":"4376_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22:29\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(20)30555-6","journal-title":"Lancet Oncol"},{"key":"4376_CR10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:702\u2013715. https:\/\/doi.org\/10.1016\/S1470-2045(21)00079-6","journal-title":"Lancet Oncol"},{"key":"4376_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/codi.14867","volume":"22","author":"C Terzi","year":"2020","unstructured":"Terzi C et al (2020) Randomized controlled trial of 8 weeks\u2019 vs 12 weeks\u2019 interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer. Colorectal Dis 22:279\u2013288. https:\/\/doi.org\/10.1111\/codi.14867","journal-title":"Colorectal Dis"},{"key":"4376_CR12","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1164\/jnccn.2021.0048","volume":"19","author":"JM Weiss","year":"2021","unstructured":"Weiss JM et al (2021) NCCN Guidelines(R) Insights: Genetic\/Familial High-Risk Assessment: Colorectal, Version 1.2021. J Natl Compr Canc Netw 19:1122\u20131132. https:\/\/doi.org\/10.1164\/jnccn.2021.0048","journal-title":"J Natl Compr Canc Netw"},{"key":"4376_CR13","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1111\/codi.15669","volume":"23","author":"L Ozer","year":"2021","unstructured":"Ozer L et al (2021) Tailored total neoadjuvant therapy for locally advanced rectal cancer: One size may not fit for all! Colorectal Dis 23:1662\u20131669. https:\/\/doi.org\/10.1111\/codi.15669","journal-title":"Colorectal Dis"},{"key":"4376_CR14","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1002\/bjs.11352","volume":"106","author":"A Zaborowski","year":"2019","unstructured":"Zaborowski A, Stakelum A, Winter DC (2019) Author response to: Total neoadjuvant therapy in rectal cancer-improvement or overtreatment? Br J Surg 106:1558. https:\/\/doi.org\/10.1002\/bjs.11352","journal-title":"Br J Surg"},{"key":"4376_CR15","doi-asserted-by":"publisher","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"4376_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16","journal-title":"Trials"},{"key":"4376_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"4376_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"4376_CR19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","volume":"61","author":"JL Peters","year":"2008","unstructured":"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2008) Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 61:991\u2013996. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.010","journal-title":"J Clin Epidemiol"},{"key":"4376_CR20","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/annonc\/mdv223","volume":"26","author":"C Fernandez-Martos","year":"2015","unstructured":"Fernandez-Martos C et al (2015) Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trialdagger. Ann Oncol 26:1722\u20131728. https:\/\/doi.org\/10.1093\/annonc\/mdv223","journal-title":"Ann Oncol"},{"key":"4376_CR21","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/annonc\/mdr473","volume":"23","author":"R Marechal","year":"2012","unstructured":"Marechal R et al (2012) Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol 23:1525\u20131530. https:\/\/doi.org\/10.1093\/annonc\/mdr473","journal-title":"Ann Oncol"},{"key":"4376_CR22","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/annonc\/mdw062","volume":"27","author":"K Bujko","year":"2016","unstructured":"Bujko K et al (2016) Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol 27:834\u2013842. https:\/\/doi.org\/10.1093\/annonc\/mdw062","journal-title":"Ann Oncol"},{"key":"4376_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bjs\/znab020","volume":"108","author":"D Chakrabarti","year":"2021","unstructured":"Chakrabarti D et al (2021) Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial. Br J Surg 108:511\u2013520. https:\/\/doi.org\/10.1093\/bjs\/znab020","journal-title":"Br J Surg"},{"key":"4376_CR24","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ijrobp.2018.04.013","volume":"101","author":"SY Kim","year":"2018","unstructured":"Kim SY et al (2018) A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14\u201303. Int J Radiat Oncol Biol Phys 101:889\u2013899. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.04.013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4376_CR25","doi-asserted-by":"publisher","unstructured":"Li LL, Wang WL, Dong HM, Wang G (2017) Prospective phase II study of neoadjuvant chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer.\u00a0Chin J Radiol Med\u00a037:107\u2013113. https:\/\/doi.org\/10.3760\/cma.j.issn.0254-5098.2017.02.005","DOI":"10.3760\/cma.j.issn.0254-5098.2017.02.005"},{"key":"4376_CR26","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/codi.13724","volume":"19","author":"J Moore","year":"2017","unstructured":"Moore J, Price T, Carruthers S, Selva-Nayagam S, Luck A, Thomas M, Hewett P (2017) Prospective randomized trial of neoadjuvant chemotherapy during the \u201cwait period\u201d following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial. Colorectal Dis 19:973\u2013979. https:\/\/doi.org\/10.1111\/codi.13724","journal-title":"Colorectal Dis"},{"key":"4376_CR27","doi-asserted-by":"publisher","unstructured":"Yang CY, Lei J, Huang JQ, Ke CF (2015) Effect of consolidation chemotherapy on neoadjuvant chemoradiotherapy for locally advanced rectal cancer.\u00a0Pract Lab Med\u00a031:2348\u20132350. https:\/\/doi.org\/10.3969\/j.issn.1006-5725.2015.14.034","DOI":"10.3969\/j.issn.1006-5725.2015.14.034"},{"key":"4376_CR28","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/SLA.0000000000005126","volume":"274","author":"DL Birrer","year":"2021","unstructured":"Birrer DL et al (2021) Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Ann Surg 274:713\u2013720. https:\/\/doi.org\/10.1097\/SLA.0000000000005126","journal-title":"Ann Surg"},{"key":"4376_CR29","doi-asserted-by":"publisher","first-page":"e1555","DOI":"10.1002\/onco.13824","volume":"26","author":"S Liu","year":"2021","unstructured":"Liu S et al (2021) Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. Oncologist 26:e1555\u2013e1566. https:\/\/doi.org\/10.1002\/onco.13824","journal-title":"Oncologist"},{"key":"4376_CR30","doi-asserted-by":"publisher","unstructured":"Riesco-Martinez MC et al (2020) Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Cancers (Basel) 12. https:\/\/doi.org\/10.3390\/cancers12123655","DOI":"10.3390\/cancers12123655"},{"key":"4376_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1515\/raon-2017-0059","volume":"52","author":"M Omejc","year":"2018","unstructured":"Omejc M, Potisek M (2018) Prognostic Significance of Tumor Regression in Locally Advanced Rectal Cancer after Preoperative Radiochemotherapy. Radiol Oncol 52:30\u201335. https:\/\/doi.org\/10.1515\/raon-2017-0059","journal-title":"Radiol Oncol"},{"key":"4376_CR32","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","volume":"16","author":"J Garcia-Aguilar","year":"2015","unstructured":"Garcia-Aguilar J et al (2015) Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 16:957\u2013966. https:\/\/doi.org\/10.1016\/S1470-2045(15)00004-2","journal-title":"Lancet Oncol"},{"key":"4376_CR33","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1200\/JCO.1999.17.8.2396","volume":"17","author":"Y Francois","year":"1999","unstructured":"Francois Y et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90\u201301 randomized trial. J Clin Oncol 17:2396. https:\/\/doi.org\/10.1200\/JCO.1999.17.8.2396","journal-title":"J Clin Oncol"},{"key":"4376_CR34","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","volume":"11","author":"M Maas","year":"2010","unstructured":"Maas M et al (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11:835\u2013844. https:\/\/doi.org\/10.1016\/S1470-2045(10)70172-8","journal-title":"Lancet Oncol"},{"key":"4376_CR35","doi-asserted-by":"publisher","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S (2017) Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol 8:39\u201348. https:\/\/doi.org\/10.21037\/jgo.2016.11.03","DOI":"10.21037\/jgo.2016.11.03"},{"key":"4376_CR36","doi-asserted-by":"publisher","unstructured":"Cercek A et al (2018) Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol 4:e180071. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0071","DOI":"10.1001\/jamaoncol.2018.0071"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-023-04376-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-023-04376-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-023-04376-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T06:16:34Z","timestamp":1703139394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-023-04376-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4376"],"URL":"https:\/\/doi.org\/10.1007\/s00384-023-04376-y","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,1]]},"assertion":[{"value":"17 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"89"}}